1443248-64-3

Upstream product

• 4659-45-4 2,6-Dichlorobenzoyl chloride 
• 83-38-5 2,6-dichlorobenzaldehyde 
• 1443242-59-8 2,2,2-trifluoro-N-((1S,4R)-4-hydroxy-1,2,3,4-tetrahydro-naphthalen-1-yl)-acetamide 
• 1443242-57-6 2,2,2-trifluoro-N-[(S)‐4‐carbonyl-1,2,3,4-tetrahydronaphthalen-1-yl]acetamide 
• 1351997-20-0 (1R,4S)-aminoN-(S)-4-hydroxy-1,2,3,4-tetrahydronaphthalen-1-ol 
• 1443248-62-1 3-(2,6-dichloro-phenyl)-6-fluoro-[1,2,4]triazolo[4,3-a]pyridine 
• 1443248-60-9 2,6-dichloro-benzoic acid N'-(5-fluoro-pyridin-2-yl)-hydrazide 
• 23357-52-0 (S)-1,2,3,4-tetrahydronapht-1-yl-amine 

Downstream Products

• 1443247-40-2 1-[5-tert-butyl-2-(2-hydroxy-ethyl)-2H-pyrazol-3-yl]-3-{(1S,4R)-4-[3-(2,6-dichloro-phenyl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea 
• 1443248-66-5 methanesulfonic acid 2-[3-tert-butyl-5-(3-{(1S,4R)-4-[3-(2,6-dichloro-phenyl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-ureido)-pyrazol-1-yl]-ethyl ester 
• 1443247-43-5 1-[5-tert-butyl-2-(2-dimethylamino-ethyl)-2H-pyrazol-3-yl]-3-{(1S,4R)-4-[3-(2,6-dichloro-phenyl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea 
• 1443247-58-2 1-(5-tert-butyl-2-(3-hydroxy-propyl)-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-(2,6-dichlorophenyl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydronaphthalen-1-yl}-urea 
• 1443247-53-7 C₃₁H₃₁Cl₂N₇O₂ 

Relevant academic research and scientific papers

DERIVATIVES OF [1, 2, 4] TRIAZOLO [4, 3 - A] PYRIDINE AS P38 - MAP KINASE INHIBITORS

Mitogen activated protein kinase (MAPK) inhibitors disclosed herein are useful for the treatment of diseases of the respiratory tract, such as chronic eosinophilic pneumonia, asthma, COPD, adult respiratory distress syndrome (ARDS), exacerbation of airways hyper-reactivity consequent to other drug therapy, and airways disease that is associated with pulmonary hypertension.

DERIVATIVES OF [1, 2, 4] TRIAZOLO [4, 3 - A] PYRIDINE AS P38 - MAP KINASE INHIBITORS

This invention relates to compounds selected in the group consisting of compounds of formula (la) to (Id) and compositions, that are p38 MAPK inhibitors, useful as anti-inflammatory agents in the treatment of, inter alia, diseases of the respiratory tract.

KINASE INHIBITORS

Compounds of formula (I) or a pharmaceutically acceptable salt thereof: wherein R2, W, A, Y and R1 are as defined in the specification, are p38 MAPK inhibitors, useful as anti-inflammatory agents in the treatment of, inter alia, diseases of the respiratory tract.

KINASE INHIBITORS

Compounds of formula (I): wherein R2, W, A, Y, and R1 are as defined in the specification, and pharmaceutically acceptable salts thereof, are p38 MAPK inhibitors, and are useful as anti-inflammatory agents in the treatment of, inter alia, diseases of the respiratory tract.